ECHOGENESIS THERAPEUTICS INC

Biotech · Private

AAV-based gene therapies with cell-type-specific promoters for genetic hearing loss

Grants
$306K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Cell type-specific gene therapy approach for TOMT-linked congenital hearing loss$305,628
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2415TRIPILL BIOTECHNOLOGY, CORP.——
2416ZYMtronix, Inc.—$3.6M
2417ProFound Therapeutics——
2418ECHOGENESIS THERAPEUTICS INC——
2419VASARYA THERAPEUTICS, INC.——
2420ANTEANA THERAPEUTICS, INC.——
2421ACHEMINALL CORPORATION——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.